CytoMed Therapeutics Ltd
Clinical-stage developer of off-the-shelf allogeneic cell immunotherapies for cancer.
GDTC | US
Overview
Corporate Details
- ISIN(s):
- SGXZ17669631
- LEI:
- Country:
- United States of America
- Address:
- #08-22 ONE COMMONWEALTH, 149544 1 COMMONWEALTH LANE
- Website:
- https://w2.cytomed.sg
Description
CytoMed Therapeutics is a clinical-stage company developing novel cell-based immunotherapies for a broad spectrum of cancers. The company focuses on creating "off-the-shelf" allogeneic therapies using its proprietary technologies to expand and engineer rare immune cells, primarily gamma delta (γδ) T cells and Natural Killer (NK) cells. These therapeutic cells are derived from healthy donors and can also be generated from induced pluripotent stem cells (iPSCs). Its pipeline encompasses multiple strategies, including unmodified cell treatments and advanced Chimeric Antigen Receptor (CAR)-modified cells, such as its CAR-γδ T cell technology. The company's mission is to produce effective and more affordable cellular treatments for both solid and hematological cancers.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all CytoMed Therapeutics Ltd filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for CytoMed Therapeutics Ltd
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for CytoMed Therapeutics Ltd via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
